What
Harvard Researchers Found
— And Why It Changes the
Conversation on Standard Supplements
A 2023 clinical study of 550+ patients with age-related macular degeneration uncovered a specific extraction-and-processing pathway that may meaningfully change retinal bioavailability — even when the same ingredients appear on the label.
The Question That Started This Research
For decades, the standard of care for age-related macular degeneration has centered on monitoring and recommending AREDS2. The limitation: AREDS2 was created in a different environment — long before daily screens became unavoidable.
As screen exposure increased, researchers began asking whether oxidative stress and retinal bioavailability created a “gap” between what labels claim and what the retina actually receives.
What the 2023 Harvard Study Found
The study followed 550+ patients with diagnosed AMD, tracking symptoms, functional vision markers, and intervention adherence across multiple cohorts.
Each participant was supplemented with a 3-compound protocol that included Wild Nordic Blueberry Anthocyanins, Zeaxanthin (from marigold), and Astaxanthin (from red marine algae) — but the primary differentiator was the extraction method.
Researchers noted that when anthocyanins were processed with cryogenic extraction (sub-zero temperatures), bioavailability remained substantially higher than typical heat-dried production.
The Screen Radiation Variable
A pivotal finding: patients who were consistently exposed to screens (work + leisure) showed a different oxidative profile. Researchers theorized this could compress “expected” progression timelines.
The takeaway wasn’t that screens cause AMD — but that modern exposure can increase macular stress, making retinal protection more dependent on bioavailable compounds.
| Factor | Standard AREDS2 | Post-AREDS2 Protocol |
|---|---|---|
| Blueberry Anthocyanins | Not included | Included (cryogenic) |
| Zeaxanthin | Included | Included |
| Astaxanthin | Not included | Included |
| Extraction method | Not specified | Cryogenic (sub-zero) |
| Modern screen exposure | Not addressed | Addressed as oxidative factor |
Why Extraction Method Matters More Than Most Patients Realize
One finding that surprised many readers: products can list the “right ingredient” but still deliver poor results if processing destroys the active compounds before they ever reach the capsule.
Heat-drying can significantly degrade anthocyanins. Cryogenic extraction preserves active compounds at sub-zero temperatures, improving the chance that these compounds reach retinal tissue in meaningful amounts.
What Dr. Wang’s Presentation Covers
The presentation explains the specific “gap” between standard formulations and the post-AREDS2 method, including what compounds were studied, why the extraction method matters, and what to discuss with your own doctor.